Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior ther...

Full description

Bibliographic Details
Main Authors: Eyre, T, Phillips, E, Linton, K, Kassam, S, Gibb, A, Allibone, S, Radford, J, Peggs, K, Burton, C, Stewart, G, LeDieu, R, Booth, C, Osborne, W, Miall, F, Eyre, D, Ardeshna, K, Collins, G
Format: Journal article
Language:English
Published: Wiley 2017

Similar Items